Follow
ioana berindan neagoe
Title
Cited by
Cited by
Year
Natural products in drug discovery: advances and opportunities
AG Atanasov, SB Zotchev, VM Dirsch, CT Supuran
Nature reviews Drug discovery 20 (3), 200-216, 2021
24862021
A comprehensive review on MAPK: a promising therapeutic target in cancer
C Braicu, M Buse, C Busuioc, R Drula, D Gulei, L Raduly, A Rusu, A Irimie, ...
Cancers 11 (10), 1618, 2019
6752019
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer
H Ling, R Spizzo, Y Atlasi, M Nicoloso, M Shimizu, RS Redis, N Nishida, ...
Genome research 23 (9), 1446-1461, 2013
6752013
MicroRNAome genome: a treasure for cancer diagnosis and therapy
I Berindan‐Neagoe, PC Monroig, B Pasculli, GA Calin
CA: a cancer journal for clinicians 64 (5), 311-336, 2014
5492014
Junk DNA and the long non-coding RNA twist in cancer genetics
H Ling, K Vincent, M Pichler, R Fodde, I Berindan-Neagoe, FJ Slack, ...
Oncogene 34 (39), 5003-5011, 2015
3382015
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells
D Arango, AJ Wilson, Q Shi, GA Corner, MJ Aranes, C Nicholas, M Lesser, ...
British journal of cancer 91 (11), 1931-1946, 2004
3262004
The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches
D Cruceriu, O Baldasici, O Balacescu, I Berindan-Neagoe
Cellular Oncology 43, 1-18, 2020
3132020
Phytol: A review of biomedical activities
MT Islam, ES Ali, SJ Uddin, S Shaw, MA Islam, MI Ahmed, MC Shill, ...
Food and chemical toxicology 121, 82-94, 2018
3132018
Apoptosis in cancer: key molecular signaling pathways and therapy targets
C Burz, I Berindan-Neagoe, O Balacescu, A Irimie
Acta oncologica 48 (6), 811-821, 2009
3112009
Exosomes as divine messengers: are they the Hermes of modern molecular oncology?
C Braicu, C Tomuleasa, P Monroig, A Cucuianu, I Berindan-Neagoe, ...
Cell Death & Differentiation 22 (1), 34-45, 2015
3072015
Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes
AA Tirpe, D Gulei, SM Ciortea, C Crivii, I Berindan-Neagoe
International journal of molecular sciences 20 (24), 6140, 2019
2902019
Progresses towards safe and efficient gene therapy vectors
S Chira, CS Jackson, I Oprea, F Ozturk, MS Pepper, I Diaconu, C Braicu, ...
Oncotarget 6 (31), 30675, 2015
2552015
The relationship between the structure and biological actions of green tea catechins
C Braicu, MR Ladomery, VS Chedea, A Irimie, I Berindan-Neagoe
Food chemistry 141 (3), 3282-3289, 2013
2242013
Overview upon miR-21 in lung cancer: focus on NSCLC
C Bica-Pop, R Cojocneanu-Petric, L Magdo, L Raduly, D Gulei, ...
Cellular and Molecular Life Sciences 75, 3539-3551, 2018
2112018
Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease
CS Cătană, IB Neagoe, V Cozma, C Magdaş, F Tăbăran, DL Dumitraşcu
World journal of gastroenterology: WJG 21 (19), 5823, 2015
2092015
CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations
RS Redis, AM Sieuwerts, MP Look, O Tudoran, C Ivan, R Spizzo, X Zhang, ...
Oncotarget 4 (10), 1748, 2013
2052013
The role of Nrf2 activity in cancer development and progression
AA Zimta, D Cenariu, A Irimie, L Magdo, SM Nabavi, AG Atanasov, ...
Cancers 11 (11), 1755, 2019
1952019
Allele-specific reprogramming of cancer metabolism by the long non-coding RNA CCAT2
RS Redis, LE Vela, W Lu, JF de Oliveira, C Ivan, C Rodriguez-Aguayo, ...
Molecular cell 61 (4), 520-534, 2016
1762016
The new era of nanotechnology, an alternative to change cancer treatment
A Jurj, C Braicu, LA Pop, C Tomuleasa, CD Gherman, I Berindan-Neagoe
Drug design, development and therapy, 2871-2890, 2017
1722017
The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis
H Ling, K Pickard, C Ivan, C Isella, M Ikuo, R Mitter, R Spizzo, MD Bullock, ...
Gut 65 (6), 977-989, 2016
1502016
The system can't perform the operation now. Try again later.
Articles 1–20